BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35263982)

  • 1. [The 493th case: recurrent edema of bilateral lower extremeties].
    Xie HY; Chen G; Li XM; Li X
    Zhonghua Nei Ke Za Zhi; 2022 Mar; 61(3):355-358. PubMed ID: 35263982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
    Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
    BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy.
    Li C; Li H; Wen YB; Li XM; Li XW
    BMC Nephrol; 2018 Dec; 19(1):354. PubMed ID: 30541581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
    Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
    Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
    Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
    J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.
    Guo Y; Wu X; Liu L; Zhang H; Yang L; Chen W
    Ren Fail; 2020 Nov; 42(1):122-130. PubMed ID: 31957527
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China.
    Guo N; Cao Y; Dai H; Yuan L; Shi L; Zhang Y
    Med Sci Monit; 2019 Dec; 25():9364-9368. PubMed ID: 31813930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phospholipase-A2 receptor antibody, 24 hours proteinuria, and serum albumin as indicators of cyclophosphamide efficacy in idiopathic membranous nephropathy.
    Xiao C; Liu Y; Zhang X; Luo L; Li X; Wang T; Tian Z; Qin X; Liu J
    J Clin Lab Anal; 2020 Sep; 34(9):e23368. PubMed ID: 32449206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
    Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
    Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
    Xie Z; Dong W; Li Z; Chen Y; Song L; Li R; Wu Y; Fu L; Liang H; Tao Y; Xie J; Wang W; Liu S; Ye Z; Shi W; Liang X
    Nephrology (Carlton); 2020 Mar; 25(3):219-229. PubMed ID: 31900967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).
    Radice A; Trezzi B; Maggiore U; Pregnolato F; Stellato T; Napodano P; Rolla D; Pesce G; D'Amico M; Santoro D; Londrino F; Ravera F; Ortisi G; Sinico RA
    Autoimmun Rev; 2016 Feb; 15(2):146-54. PubMed ID: 26527329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies.
    Ou JY; Chen YW; Li TL; Shan HZ; Cui S; Lai JJ; Xiao Y
    Nephrol Ther; 2022 Apr; 18(2):104-112. PubMed ID: 35074299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
    Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
    Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rituximab in patients with PLA2R-associated membranous nephropathy and malignancy.
    Guo Y; Ren M; Wang Y; Zhai Z; Yu L; Wang L; Tang L
    Int Immunopharmacol; 2024 Jan; 126():111327. PubMed ID: 38056198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.
    Bech AP; Hofstra JM; Brenchley PE; Wetzels JF
    Clin J Am Soc Nephrol; 2014 Aug; 9(8):1386-92. PubMed ID: 25035272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.
    Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1883-90. PubMed ID: 25267554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.
    Hoxha E; Thiele I; Zahner G; Panzer U; Harendza S; Stahl RA
    J Am Soc Nephrol; 2014 Jun; 25(6):1357-66. PubMed ID: 24610926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The relationship between anti-phospholipase A2 receptor antibody and idiopathic membranous nephropathy].
    Lin W; Li H; Li X; Qin Y; Su Y; Yu Y; Guan Y; Duan L; Li Y; Wen Y; Li X
    Zhonghua Nei Ke Za Zhi; 2015 Sep; 54(9):783-8. PubMed ID: 26674797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.
    Provatopoulou S; Kalavrizioti D; Stangou M; Kouri MN; Kalliakmani P; Papasotiriou M; Papachristou E; Goumenos DS; Papagianni A
    Rom J Intern Med; 2019 Jun; 57(2):141-150. PubMed ID: 30864406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of anti-phospholipasea2-receptor antibodies with clinical course of idiopathic membranous nephropathy.
    Thokhonelidze I; Maglakelidze N; Sarishvili N; Kasradze T; Dalakishvili K
    Georgian Med News; 2015 Apr; (241):49-53. PubMed ID: 25953939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.